BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Parmodia (Pemafibrate) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Parmodia (Pemafibrate)\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07634484-1047@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Parmodia (Pemafibrate): Phase 4 readout est. (NCT07634484)
DESCRIPTION:Parmodia (Pemafibrate)\, phase 4\, Atherosclerotic Cardiovascul
 ar Disease.\nStudy: A Post-Marketing Clinical Trial of Pemafibrate in Pati
 ents ｗith Hypercholesterolemia and Inadequate Response to Statins\nEstim
 ated primary completion: 31 July 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/pemafibrate#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07634484
URL:https://assetmemo.bio/drug/pemafibrate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07562178-1047@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Parmodia (Pemafibrate): Phase na readout est. (NCT07562178)
DESCRIPTION:Parmodia (Pemafibrate)\, phase na.\nStudy: Pemafibrate for Symp
 tomatic ICAS RCT\nEstimated primary completion: 31 March 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/pemafibrate#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07562178
URL:https://assetmemo.bio/drug/pemafibrate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
